A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK

Background: Economic information is necessary for rational decision-making in health care. Many European countries require financial impact statements prior to drug approval, and many health care organizations in the USA consider cost-effectiveness when making formulary decisions. We report the find...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2002-10, Vol.13 (10), p.1590-1597
Hauptverfasser:	Smith, D. H., Adams, J. R., Johnston, S. R. D., Gordon, A., Drummond, M. F., Bennett, C. L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic agents Antineoplastic Agents - administration & dosage Antineoplastic Agents - economics Antineoplastic Agents - therapeutic use Biological and medical sciences Blood Transfusion Chemotherapy Cost-Benefit Analysis Decision Making Doxorubicin - administration & dosage Doxorubicin - economics Doxorubicin - therapeutic use Drug Costs - statistics & numerical data economic analysis Female Health Care Costs - statistics & numerical data Health Policy Hospitalization Humans Infusions, Intravenous Key words: cost Medical sciences Middle Aged ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - economics Pharmacology. Drug treatments PLD Randomized Controlled Trials as Topic topotecan Topotecan - administration & dosage Topotecan - economics Topotecan - therapeutic use United Kingdom United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!